Abstracts tagged "Behçet’s Syndrome"

Abstract Number: 1564 • ACR Convergence 2023
Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease
fatma Alibaz-Öner¹, Rabia Ergelen², Seda Kutluğ Ağaçkıran³, Fatma Temiz⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Marmara University, School of Medicine, Department of Radiology, Istanbul, Turkey, ³Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Marmara University, School of Medicine, Department of Internal Medicine, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, ⁶Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
Background/Purpose: The diagnosis of Behçet's disease (BD) is mainly based on multi-systemic clinical manifestations after ruling out other potential causes. There is no specific diagnostic…
Abstract Number: 0701 • ACR Convergence 2023
Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Jose Luis Martin-Varillas³, Carmen Alvarez Reguera¹, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Raul Fernandez¹, Ivan Ferraz Amaro⁶, Jose Luis Hernandez¹ and Ricardo Blanco⁷, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital de Sierrallana, Santander, Spain, ⁶Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…
Abstract Number: 2517 • ACR Convergence 2023
The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease
Erdem Bektas¹, Rabia Deniz², Zeliha Emrence³, Sema Sırma Ekmekci³, Neslihan Abacı³, Shirkhan Amikishiyev⁴, Yasemin Yalçınkaya⁴, Bahar Artim Esen⁴, Murat Inanç⁵ and Ahmet Gul⁶, ¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, ²University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, ³Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: Behcet disease (BD) is a multisystemic inflammatory disease of unknown etiology. BD has been classified among the neutrophilic dermatosis, and neutrophil extracellular traps (NETs)…
Abstract Number: 0801 • ACR Convergence 2023
LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease
Zhimian Wang, Xin Yu, Hua Chen and Wenjie Zheng, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Dysregulated Th17 cells are implicated in Behçet's disease (BD). However, the underlying mechanism remains unclear. Here we aim to elucidate the mechanism of forkhead…
Abstract Number: 2519 • ACR Convergence 2023
A Phase II Clinical Study to Investigate the Efficacy and Safety of Hemay005 Tablets in Patients with Active Behçet`sDisease
Charles Jones¹, Zhanguo Li², Zhuoli Zhang³, Jian Wu⁴, Guixiu Shi⁵, Wenjie Zheng⁶, Jianping Tang⁷, Xiaobing Wang⁸, Lie Dai⁹, Lin Chen¹⁰, Yasong Li¹¹, Ling Wu¹², Yongfu Wang¹³, Shengyun Liu¹⁴, Yao Ke¹⁵, Jin Lin¹⁶, Zhenchun Zhang¹⁷, Jiankang Hu¹⁸, Wantai Dang¹⁹, Songlou Yin²⁰, Xin Tang²¹, Mingfei Zhu²², Jinfeng Lin²², Richard Jones²², Weiguo Wan²³ and xianjun Hu²², ¹Hemay Pharmaceuticals, Tianjin, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ³Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ⁴Suzhou University Affiliated First Hospital, Suzhou, China, ⁵the First Affiliated Hospital of Xiamen University, Xiamen, China, ⁶Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ⁷Shanghai Tongji Hospital, Shanghai, China, ⁸The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁹Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ¹⁰Jilin Provincial People's Hospital, Changchun, China, ¹¹11Zhejiang Provincial People's Hospital, Hangzhou, China, ¹²University of Hong Kong Shenzhen Hospital, Shenzhen, China, ¹³The First Affiliated Hospital of Baotou Medical College, Baotou, China, ¹⁴The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ¹⁵Jiangsu Provincial People's Hospital, Nanjing, China, ¹⁶The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹⁷Linyi People's Hospital, Linyi, China, ¹⁸Pingxiang People’s Hospital, PingXiang, China, ¹⁹The First Affiliated Hospital of Chengdu Medical College, Chengdu, China, ²⁰Xuzhou Medical University Affiliated Hospital, Xuzhou, China, ²¹Bestudy (Shanghai) Medical Technology Co., Ltd, Shanghai, China, ²²Clinical Department, Tianjin Hemay Pharmaceutical Co., Ltd., Tianjin, China, ²³Huashan Hospital Affiliated to Fudan University, Shanghai, China
Background/Purpose: Behçet's disease (BD) is a chronic and recurrent vascular inflammatory disease with major manifestations including oral ulcers, genital ulcers, skin damage and ophthalmitis, and…
Abstract Number: 1126 • ACR Convergence 2023
Identification of Clinical Phenotypes in Behçet’s Disease Using a Cluster Analysis
Ana Serrano-Combarro¹, Jose Luis Martin-Varillas², Raul Fernandez-Ramon³, Lara Sanchez-Bilbao⁴, Carmen Alvarez Reguera³, ELENA Aurrecoechea⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Hospital de Laredo, Laredo, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵HOSPITAL SIERRALLANA, Cantabria, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behcet's disease (BD) is a variable-vessel vasculitis with a high variability of clinical manifestations. The objective of our study was to identify clinical phenotypes…
Abstract Number: 1228 • ACR Convergence 2023
Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach
Caterina Matucci-Cerinic¹, helene Palluy², Sulaiman Al-Mayouf³, Paul Brogan⁴, Luca Cantarini⁵, Ahmet Gul⁶, Ozgur Kasapcopur⁷, Jasmin B. Kuemmerle-Deschner⁸, Seza Ozen⁹, david saadoun¹⁰, Farhad Shahram¹¹, Francesca Bovis¹², Eugenia mosci¹³, Nicolino Ruperto¹⁴, Marco Gattorno¹⁵ and Isabelle Kone-Paut¹⁶, ¹DINOGMI, University of Genoa; IRCCS Istituto Giannina Gaslini, UOC Rheumatology and autoinflammatory diseases, Genova, Italy, ²Pediatric rheumatology and CEREMAIA, Bicêtre hospital, APHP, University of Paris Saclay, Paris, France, ³King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ⁴UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁵Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁷Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁸med.uni-tuebingen, Tübingen, Germany, ⁹Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁰Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Inflammatoires et de l’Amylose inflammatoire, F-75013, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière., Neuilly sur Seine, France, ¹¹Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran, ¹²Dept of Health Sciences (DISSAL), University of Genoa, Genova, Italy, ¹³UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹⁴IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ¹⁵UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ¹⁶Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France
Background/Purpose: Behçet's disease (BD) is an autoinflammatory disease characterized by a variable vessel vasculitis. In the past, several criteria have been created for adult BD…
Abstract Number: 1248 • ACR Convergence 2023
Thrombotic Manifestations in Pediatric Behçet Disease Patients: A Multicentre Comparative Study from EUROFEVER Registry
Maria Vincenza Mastrolia¹, Caterina Matucci-Cerinic², Seza Ozen³, Ozgur Kasapcopur⁴, Carla Gaggiano⁵, Isabelle Kone-Paut⁶, Luca Cantarini⁵, Perrine Dusser⁷, Ümmüşen Kaya-Akça⁸, Mehmet Yildiz⁹, Juergen Brunner¹⁰, Giovanni Filocamo¹¹, Romina Gallizzi¹², Antonella Insalaco¹³, Serena Pastore¹⁴, Donato Rigante¹⁵, Judith Sanchez-Manubens¹⁶, Elena Tsitsami¹⁷, Marco Gattorno¹⁸ and Gabriele Simonini¹⁹, ¹NEUROFARBA Department, University of Florence, Florence, Italy, ²DINOGMI, University of Genoa; IRCCS Istituto Giannina Gaslini, UOC Rheumatology and autoinflammatory diseases, Genova, Italy, ³Hacettepe University Medical Faculty, Ankara, Turkey, ⁴Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy, ⁶Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, ⁷Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ⁸Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Instanbul, Turkey, ¹⁰Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ¹¹Pediatric Immunorheumatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, MIlan, Italy, ¹²Department of Medical of Health Sciences, Magna Graecia University, Catanzaro, Italy, ¹³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ¹⁴Institute for Maternal and Child Health, RCCS “Burlo Garofolo", Trieste, Italy, ¹⁵Department of Life Sciences and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy, ¹⁶Pediatric Rheumatology, Section Pediatric Service, Parc Taulí Sabadell University Hospital, Institute for Research and Innovation I3PT, Sant Joan de Deu Hospital, Autonomous University of Barcelona, Barcelona, Spain, ¹⁷Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital "Aghia Sophia", University of Athens, Athens, Greece, ¹⁸UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ¹⁹Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: Arterial and venous thrombosis occurs in 6.6 to 38.4% of pediatric Behçet disease (BD) and cerebral sinus is one of the most involved districts.…
Abstract Number: 1554 • ACR Convergence 2023
Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study
Audrey Hermant¹, Yann Nguyen², Fleur Cohen³, Antoine Baudet⁴, Alban DEROUX⁵, Vincent Poindron⁶, Cécile-Audrey Durel⁷, Nicolas Girszyn⁸, Noémie Le Gouellec⁹, Benedicte Rouviere¹⁰, Helder Gil¹¹, Francois Maurier¹², Nicolas Noel¹³, Loic Raffray¹⁴, Hubert De Boysson¹⁵, Benoit Faucher¹⁶, Bertrand Godeau¹⁷, Pierre Lozach¹⁸, Claude Bachmeyer¹⁹, Alice Berezne⁴, Gilles Blaison²⁰, Brice Castel²¹, Guillaume Gondran²², Matthieu Groh²³, Stéphane Giorgiutti²⁴, Jeremy Keraen²⁵, Julie Magnant²⁶, Sebastien Monnier²⁷, Philippe Blanche²⁸, Dominique Monnet²⁹, Antoine Brezin²⁹ and Benjamin Terrier³⁰, ¹Hopital Cochin, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Sorbonne Université, Paris, France, ⁴CH Annecy, Annecy, France, ⁵CHU de Grenoble, Grenoble, France, ⁶Strasbourg, Strasbourg, France, ⁷CHU Lyon, Lyon, France, ⁸Rouen, Rouen, France, ⁹CH Valenciennes, Valenciennes, France, ¹⁰CHU Brest, Brest, France, ¹¹CHU Besancon, Besançon, France, ¹²CH Metz, Metz, France, ¹³CHU Bicetre, Le Kremlin-Bicêtre, France, ¹⁴CHU la Réunion, La Réunion, France, ¹⁵CHU Caen, Caen, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Henri Mondor, Créteil, France, ¹⁸CH Le Mans, Le Mans, France, ¹⁹CHU Tenon, Paris, France, ²⁰Hôpital Louis PASTEUR, Colmar, France, ²¹CH Tarbes, Tarbes, France, ²²CHU Limoges, Limoges, France, ²³National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ²⁴CHRU Strasbourg, Strasbourg, France, ²⁵CH Quimper, Quimper, France, ²⁶CHU Tours, Tours, France, ²⁷CH Versailles, Versailles, France, ²⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²⁹CHU Cochin, Paris, France, ³⁰Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The management of severe ocular involvement in Behçet's disease (BD) is an important issue with major functional implications due to the risk of blindness.…
Abstract Number: 1555 • ACR Convergence 2023
Axial Spondyloarthritis in Patients with Gastrointestinal Involvement of Behçet Syndrome
Musab Ozturk¹, Sinem Nihal Esatoglu², Ibrahim Hatemi³, Aykut Ferhat Celik³, Osman Aykan Kargin⁴, Ahmet Oz⁴, Erkan Yilmaz⁵, Didar Ucar⁶, Melike Melikoglu², Hasan Yazici⁷, Ibrahim Adaletli⁴ and Gulen Hatemi², ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Radiology, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Tissue Typing Laboratory, Istanbul, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ⁷Academic Hospital, Istanbul, Turkey
Background/Purpose: Controlled studies have shown that radiographic sacroiliitis was not increased in Behçet syndrome (BS), compared to other inflammatory diseases. However, gastrointestinal involvement of Behçet…
Abstract Number: 127 • 2023 Pediatric Rheumatology Symposium
What’s in a Name? A20 Protein Expression in an in Vitro Model of A20 Haploinsufficiency
Patricia Pontes Aires¹, DANIELA GERENT PETRY PIOTTO¹, Andre Cunha¹, Sandro Perazzio² and Maria Teresa Terreri³, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade de So Paulo; Fleury Laboratories, São Paulo, Brazil, ³UNIFESP, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor alpha (TNF-alpha) induced protein 3 gene, or TNFAIP3, encodes the A20 protein, an important regulator of the NF-κB pathway. Since its…
Abstract Number: 0695 • ACR Convergence 2022
Epidemiology of Behçet’s Disease in Northern Spain
Carmen Alvarez Reguera¹, guillermo Suárez-Amorin¹, Rosalía Demetrio-Pablo¹, Raúl fernández-ramón¹, Alba Herrero-Morant², Lara Sánchez-Bilbao¹, David Martínez-López¹, José Luis Martín-Varillas³, Santos Castañeda⁴, Miguel Ángel González-Gay⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ³Hospital de Laredo, Laredo, Cantabria, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The prevalence of Behçet’s disease (BD) has a considerable geographical and temporal variability. Data regarding epidemiology in Spain are limited. Our study aimed to…
Abstract Number: 1567 • ACR Convergence 2022
Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol
José Luis Martín-Varillas¹, Lara Sánchez-Bilbao², Vanesa Calvo Río³, Alf Adán⁴, Inés Hernanz Rodríguez⁴, Miguel Cordero Coma⁵, David Díaz Valle⁶, Patricia Fanlo⁷, Juan Ramón de Dios⁸, A. Garcia-Aparicio⁹, Sergio Rodriguez Montero¹⁰, Vega Jovani Casano¹¹, Patricia Moya Alvarado¹², eva Peña Sainz-Pardo¹³, José Luis Hernández² and Ricardo Blanco¹⁴, ¹Hospital de Laredo, Laredo, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴H. Clinic, Barcelona, Spain, ⁵Hospital de León, León, Spain, ⁶Hospital Clínico San Carlos, Madrid, Spain, ⁷Complejo Hospitalario de Navarra, Navarra, Spain, ⁸Hospital de Araba, Araba, Spain, ⁹Hospital Universitario de Toledo, Toledo, Spain, ¹⁰Virgen de Valme University Hospital, Sevilla, Spain, ¹¹National Health system, Alicante, Spain, ¹²Hospital Parc Tauli, Barcelona, Spain, ¹³Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Cystoid Macular Edema (CME) is the leading cause of blindness in non-infectious uveitis. Behçet's disease (BD) is one of the diseases most frequently associated…
Abstract Number: 1041 • ACR Convergence 2022
Tofacitinib in Refractory Uveitis – an Observational Study
Nikhil Gupta¹ and Deepankur Mahajan², ¹Centre for Arthritis and Rheumatological diseases in Delhi, New Delhi, India, ²Mahajan Eye Centre, New Delhi, India
Background/Purpose: To evaluate the effect of generic tofacitinib in refractory uveitis patients.Methods: It was a prospective observational study of 23 patients of refractory anterior uveitis.…
Abstract Number: 1701 • ACR Convergence 2022
High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology
Patricia Pontes Aires¹, André Cunha¹, DANIELA GERENT PETRY PIOTTO¹, Maria Teresa Terreri² and Sandro Perazzio¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidad Federal São Paulo, São Paulo, Brazil
Background/Purpose: A20 haploinsufficiency (A20HA), an important monogenic etiology of Behçet's disease (BD), is caused by loss-of-function mutations in TNFAIP3. Although monocytes play an important role…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].